Ready to try the MindBody GLP-1 System
This guide covers everything you need to know about grey market tirzepatide: what it actually is, why the FDA is sounding alarms, what contamination testing reveals about these products, how to spot unsafe sources, and what safer alternatives exist for people who cannot afford brand-name tirzepatide
This gives you a baseline to work from
Not sure if a B12 Injection is right for you
Our finding of similar incidence of non-fatal cardiovascular outcomes with GLP1-RA compared to DPP4i is in line with the recently published FLOW study that randomized people with early to mid-stage CKD to semaglutide or placebo, which reported similar incidence of non-fatal myocardial infarction and non-fatal stroke across the semaglutide and placebo treated groups, despite a significantly reduced risk of major kidney disease events and all-cause death 44
References Pasternak B, Wintzell V, Hvidd A, et al